About Traders News Source:
Big Opportunities in Small Cap’s
Traders News Source recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!
January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days- http://finance.yahoo.com/news/himax-technologies-review-4q-2016-130000319.html
February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% – http://finance.yahoo.com/news/superconductor-technologies-potential-revolutionize-smart-130000844.html
March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members- http://finance.yahoo.com/news/traders-news-issues-comprehensive-report-130000743.html
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone.
Traders News Source Mission Statement
Akers Biosciences Inc (NASDAQ:AKER) develops and manufactures rapid screening and testing products designed to provide health care professional and consumers with quick and cost-effective health care information.
Akers has three lines generating revenue including Clinical Diagnostics, Safety Diagnostics & Wellness. Under these segments, it is developing proprietary, diagnostic technologies that increase the frequency at which clinicians, and in some cases consumers, can get accurate health information and has a number of products in the portfolio. Aker is focusing on gaining a meaningful market share in its segments, although it faces intense competition from traditional products.
Aker recently announced that it received an initial order for the Company’s rapid cholesterol self-test from First Check Diagnostics, LLC (“First Check”), the exclusive distributor for this product in the United States, for sale under their popular “First Check” brand.
As per management, this order is a great endorsement of its rapid testing technology & they are extremely bullish on having this over-the-counter health and wellness product on the shelves of major US retailers under the distinguished First Check brand.
The sales of the Company’s flagship products are already on an upward trajectory and with this recent development; Aker is likely to witness strong demand for rapid testing technology as well.
Point-of-care diagnostics is a multi-billion dollar health care market that is well poised for robust growth over the near to medium term and with over 73 million adults in the US deemed to have high bad cholesterol; Aker should have a strong order book & opportunities around rapid cholesterol test. The company is aggressively focusing to building this revenue stream with its distribution partner and providing consumers with a fast, convenient and meaningful way to evaluate and manage their cholesterol.
About the Company:
Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies.
The Company commenced research and development operations in September 1989, and until 2005 had devoted substantially all its efforts to establishing the new business.
The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
The company recently announced that its rapid, cholesterol self-test would soon be on the shelves of major US retailers under the First Check brand after it received a first order from First Check.
About First Check: First Check Diagnostics is Aker’s exclusive distributor in the US. It will sell the product under its “First Check” brand, through US retailers such as CVS, Rite Aid, Target, Kmart and others.
Unique differentiating factors of Tri-Cholesterol: The Tri-Cholesterol “Check” test is disposable, uses just a finger-stick blood sample and gives a result in only 5 minutes. The test has FDA 510(k) clearance in the United States; as well as a CE mark for the European Economic Area.
Potential market: According to the United States Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the United States have high ‘bad cholesterol’ and less than 1 in every 3 of them has the condition under control. Too much cholesterol puts people at risk for heart disease and stroke, two leading causes of death in the United States. However, with responsible actions such as self-testing with Akers Bio’s Tri-Cholesterol “Check” test, people can take steps to manage their cholesterol levels and lower their risk.
US Patent for Akers Wellness(TM) Tests Cartridge: Previously, during Feb’17, Aker announced that the United States Patent and Trademark Office has allowed a patent covering Akers Bio’s proprietary cartridge for the optical scanning device utilized in the Company’s BreathScan Lync™ technology.
OxiChek™ is now fully commercialized and selling through the Company’s distributor, Aero-Med, to anti-aging, functional and integrative health and wellness treatment practitioners in the US.
The Company looks forward to providing further updates on the commercialization progress of Akers Wellness™ tests during 2017.
Agreement with GNYHA Services: Additionally, the company has also signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the Company’s flagship rapid tests for heparin-induced thrombocytopenia across GNYHA’s network of over 300 member hospitals and health systems.
In fact, Aker experienced strong growth from flagship PIFA Heparin/PF4 Rapid Assay product sales without any contribution from China in Q3 2016
Closing of Public Offering: In order to fund the incremental working capital requirement, Aker recently raised $2,147,400 through public offering. The funds raised will be used for working capital as well as to accelerate growth in the US and in international markets, further develop new customers and launch new diagnostic products.
Risk Factors & Key Stock Influences:
The company’s ability to expand the domestic and international distribution of its PIFA Heparin/PF4 rapid assays, along with meaningful, commercialization of health and wellness product line is a critical business sensitivity factor. Aker’s business might take a substantial hit, if it fails to capture significant market share or interest of the health care community with its Heparin test or other products.
Company’s liquidity is impinged by continued negative cash flows/profitability and large incremental working capital requirement. Therefore, its ability to substantially improving its profitability would remain a critical operational challenge for the company.
The company has announced several positive developments in the recent past & should the company come out with better than expected guidance or experience another positive development, the stock could react positively.
As per recent projections, working capital situation of Aker is expected to remain comfortable for next 12 months. However, given the fact that the company is still under development stage & is continuously burning cash, any material time or cost overruns in its ongoing & future project could result in the possible inability of the Company to continue as a going concern.
Earnings Review: Akers’ revenue for the three months ended September 30, 2016 totaled $613,198, a 262% increase from the same period in 2015. The table below summarizes our revenue by product line for the three months ended September 30, 2016 and 2015 as well as the percentage of change year-over-year:
Profitability: For Q3 – 2016, Aker’s gross margin improved significantly, rising to 61% (2015: (5)%) for the three months ended September 30, 2016. The improvement is attributed to higher selling prices for the PIFA Heparin PF/4 Rapid Assay products; improved volumes and a significantly different component mix for the MPC products and the continued implementation of the new inventory and cost management procedures.
Cash Flow & Balance Sheet: At September 30, 2016, Akers had cash of $195,860, working capital of $2,537,197, and stockholders’ equity of $4,470,500 and an accumulated deficit of $96,383,706. The Company believes that its current working capital position will be sufficient to meet its estimated cash needs for at least the next 12 months.
On Wednesday, March 29th, 2017, AKER shares increased by 67.86% to $2.35 on an average volume of 78,294.00 shares exchanging hands. Market capitalization is $9.97 million. The current RSI is 86.67
In the past 52 weeks, shares of Aker have traded as low as $1.15 and as high as $3.70.
At $2.35, shares of Aker are trading above their 50-day moving above their average (MA) at $1.28 and just below their 200-day MA at $2.37
The present support and resistance levels for the stock are at $1.8 & $2.90 respectively.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.